ID   NGP
AC   CVCL_2141
DR   BioSample; SAMN03473431
DR   Cell_Model_Passport; SIDM01785
DR   Cosmic; 717421
DR   Cosmic; 923823
DR   Cosmic; 930071
DR   Cosmic; 1019937
DR   Cosmic; 1109120
DR   Cosmic; 1161999
DR   Cosmic; 1167422
DR   Cosmic; 1167988
DR   Cosmic; 1526637
DR   Cosmic; 2058106
DR   Cosmic; 2393638
DR   DepMap; ACH-001366
DR   DSMZ; ACC-676
DR   GEO; GSM453633
DR   GEO; GSM692865
DR   GEO; GSM2371249
DR   GEO; GSM2394382
DR   GEO; GSM4104589
DR   GEO; GSM4104590
DR   GEO; GSM4105333
DR   GEO; GSM4105334
DR   GEO; GSM4105335
DR   GEO; GSM4105336
DR   GEO; GSM4105337
DR   IARC_TP53; 23601
DR   LINCS_HMS; 51099
DR   LINCS_LDP; LCL-2103
DR   Progenetix; CVCL_2141
DR   Wikidata; Q54930471
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=922665;
RX   PubMed=6888561;
RX   PubMed=8490657;
RX   PubMed=9283597;
RX   PubMed=11550280;
RX   PubMed=15150091;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=23202128;
RX   PubMed=24466371;
RX   PubMed=28350380;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~50-70 hours (DSMZ).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Trp (c.423C>G); ClinVar=VCV000376564; Zygosity=Unspecified (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: ATAC-seq.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Lung.
ST   Source(s): DepMap; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,12
ST   D16S539: 8,11
ST   D18S51: 15
ST   D21S11: 32,33.1
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 11,12
ST   FGA: 19,23
ST   Penta D: 8,10
ST   Penta E: 11,15
ST   TH01: 9
ST   TPOX: 6,9
ST   vWA: 16,21
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   2Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 25
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1;
RA   Brodeur G.M., Sekhon G., Goldstein M.N.;
RT   "Chromosomal aberrations in human neuroblastomas.";
RL   Cancer 40:2256-2263(1977).
//
RX   PubMed=6888561; DOI=10.1038/305245a0;
RA   Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M.,
RA   Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.;
RT   "Amplified DNA with limited homology to myc cellular oncogene is
RT   shared by human neuroblastoma cell lines and a neuroblastoma tumour.";
RL   Nature 305:245-248(1983).
//
RX   PubMed=8490657; DOI=10.1038/ng0193-62;
RA   The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G.,
RA   Gusella J.F., Bernards A.;
RT   "Neurofibromatosis type 1 gene mutations in neuroblastoma.";
RL   Nat. Genet. 3:62-66(1993).
//
RX   PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7;
RA   Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R.,
RA   De Paepe A., Cremer T., Speleman F.;
RT   "Comparative genomic hybridization analysis of human neuroblastomas:
RT   detection of distal 1p deletions and further molecular genetic
RT   characterization of neuroblastoma cell lines.";
RL   Cancer Genet. Cytogenet. 97:135-142(1997).
//
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//